Maximizing treatment benefits in type 2 diabetes by affordable oral anti diabetes agents in India


  • Ashok K. Das Department of Endocrinology and Medicine, Pondicherry Institute of Medical Sciences, Puducherry, India
  • B. Krishnakumar Department of Cardiology, Government Medical College, Thiruvananthapuram, Kerala, India
  • Ajish T. P. Department of Endocrinologist, Travancore Medical College, Kollam, Kerala, India
  • Raka Sheohare Department of Diabetology, Lifeline Madhumeet Diabetes hospital, Raipur, Chhattisgarh, India
  • Sachin Chittawar Department of Endocrinology, Harmony Super Specialty Clinic, Bhopal, Madhya Pradesh, India



Diabetes mellitus, Oral anti diabetes agents, Efficacy, Safety, Affordable therapy


Diabetes mellitus (DM) is a global epidemic with number of cases rising exponentially with each decade. What makes it more concerning is its association with numerous complications like cardiovascular diseases, end-stage renal disease, neuropathy, and retinopathy. In India, the management of this disease mainly involves out‑of‑pocket expense and contributes to catastrophic health expenditure and distress financing. Thus, the need of the hour is to make oral anti diabetes agents (OADs) affordable and accessible so that maximum number of patients can avail treatment benefits in diabetes care. This review article focuses on the currently available low cost OADs such as sulfonylureas, metformin, thiazolidinediones, alpha glucosidase inhibitors, dipeptidyl-peptidase 4 (DPP4) inhibitors and sodium-glucose co-transporter-2 (SGLT2) inhibitors explaining their efficacy and safety from recent clinical evidence and those going off patent and becoming much affordable in their generic form. This information will help family physicians make rational choices for their type 2 DM (T2DM) patients.


IDF DIABETES ATLAS. Ninth edition 2019. International diabetes federation. Available at: Accessed on 25 May 2021.

Thibault V, Bélanger M, LeBlanc E, Babin L, Halpine S, Greene B, et al. Factors that could explain the increasing prevalence of type 2 diabetes among adults in a Canadian province: a critical review and analysis. Diabetol Metab Syndr. 2016;8(1):71.

Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. WJD. 2016;7(17):354.

Singla R, Bindra J, Singla A, Gupta Y, Kalra S. Drug prescription patterns and cost analysis of diabetes therapy in India: Audit of an endocrine practice. Indian J Endocr Metab. 2019;23:40-5.

Joshi SR. Metformin: old wine in new bottle-evolving technology and therapy in diabetes. J Assoc Physicians India. 2005;53:963-72.

Bramante C, Ingraham N, Murray T. Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19. medRxiv. 2020.

Crouse A, Grimes T, Li P. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. medRxiv. 2020.

Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocr Metab. 2015;19:577-96.

Sola D, Rossi L, Schianca GP. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840-8.

Costello RA, Shivkumar A. Sulfonylureas. In: StatPearl. Treasure Island (FL): StatPearls Publishing. 2020.

Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care. 1996;19:849-56.

Hirst JA, Farmer AJ, Dyar A. Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis. Diabetologia. 2013;56(5):973-84.

Zhu H, Zhu S, Zhang X, Guo Y, Shi Y, Chen Z, et al. Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: Meta‑analysis of randomized controlled trials. Diabetol Metab Syndr. 2013;5:70.

Kalra S, Bahendeka S, Sahay R. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International task force. Indian J Endocr Metab. 2018;22:132-57.

Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, et al. Efficacy of glimepiride/metformin fixed‑dose combination vs. metformin uptitration in type 2 diabetic patients inadequately controlled on low‑dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig. 2014;5:701-8.

Shunmugavelu M, Shah T, Vijaya Kumar G. Myths and Facts About Glimepiride. JAPI. 2019;24-6.

Dor Y, Glaser B. β‑cell dedifferentiation and type 2 diabetes. N Engl J Med. 2013;368:572-3.

Gudipaty L, Rosenfeld NK, Fuller CS. Effect of exenatide, sitagliptin, or glimepiride on ß‑cell secretory capacity in early type 2 diabetes. Diabetes Care. 2014;37:2451-8.

Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535-42.

Devarajan TV, Venkataraman S, Kandasamy N. Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study. Indian J Endocrinol Metab. 2017;21(5):745-50.

Landman GWD, de Bock GH, van Hateren KJJ, van Dijk PR, Groenier KH, Gans ROB, et al. Safety and Efficacy of Gliclazide as Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials. Letizia Hribal M, editor. PLoS ONE. 2014;9(2):82880.

Green JB, Feinglos MN. Are sulfonylureas passé? Curr Diab Rep. 2006;6(5):373-7.

Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA (1c) and body weight in Type 2 diabetes: Results of a 1.5‑year follow‑up study. Diabetes Res Clin Pract. 2003;61:13-9.

Rosenstock J, Kahn SE, Johansen OE. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes The CAROLINA Randomized Clinical Trial. JAMA. 2019;322:1155-66.

Kalra S, Ghosh S, Das AK, Nair T. Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel. Indian Heart J. 2020;72(1):7-13.

John M, Kalra S, Nair T. Modern sulfonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy? Indian Heart J. 2020;72(4):312-5.

Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care. 2009;32:2068-74.

Rados DV, Pinto LC, Remonti LR. The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. PLOS Medicine. 2016;3:43-51.

Dormandy JA, Charbonnel B, Eckland DJ, PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005;366(9493):1279-89.

Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916-22.

Pai SA, Kshirsagar NA. Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report. Indian J Med Res. 2016;144:672-81.

DeFronzo RA, Inzucchi S, Abdul-Ghani M. Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16(2):133-43.

Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest. 1994;24(3):3-10.

Glycemic pentad Glycemic Pentad Forum. Consensus statement. 2017. Available at: Accessed on 12 February 2021.

Cahn A, Raz I. Emerging gliptins for type 2 diabetes. Expert Opin Emerg Drugs. 2013;18:245-58.

Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Teneligliptin in management of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2016;9:251-60.

Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S. Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study). Diabetes Metab Syndr Obes. 2016;9:347-53.

Ghosh S, Tiwaskar M, Chawla R, Jaggi S, Asirvatham A, Panikar V. Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2). Diabetes Ther. 2020;11(10):2257-68.

Diabetes drug price to halve as patent expires; cheaper versions expected soon. Available at: Accessed on 13 February 2021.

Ahrén B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes. 2010;3:31-41.

Chowdhury S, Chadha M, Ghosh S. Indian expert review on use of teneligliptin in patients with diabetes and its safety and efficacy (INTENSE). JAPI. 2021;69.

DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5-14.

Markham A. Remogliflozin etabonate: First global approval. Drugs. 2019;79:1157-61.

Mohan V, Mithal A, Joshi SR, Aravind SR, Chowdhury S. Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy. Drug Des Devel Ther. 2020;14:2487-501.

Aggarwal A, Wadhwa R, Kapoor D. High prevalence of genital mycotic infections with sodium-glucose co-transporter 2 inhibitors among Indian patients with type 2 diabetes. Indian J Endocr Metab. 2019;23:9-13.

Hurren KM, Dunham MW. Are thiazolidinediones a preferred drug treatment for type 2 diabetes? Expert Opin Pharmacother. 2021;22(2):131-3.

Meneghini LF, Orozco-Beltran D, Khunti K. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab. 2011;96(11):3337-53.

Coleman RL, Scott CAB, Lang Z. Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. Cardiovasc Diabetol. 2019;18(1):135.

Dabhi AS, Bhatt NR, Shah MJ. Voglibose: an alpha glucosidase inhibitor. J Clin Diagn Res. 2013;7(12):3023-7.

Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci. 2012;8(5):899-906.

Khalse M, Bhargava A. A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors. Indian J Endocr Metab. 2018;22:689-95.

Jones MR, Hall OM, Kaye AM, Kaye AD. Drug-induced acute pancreatitis: A review. Ochsner J. 2015;15(1):45-51.

Kadowaki T, Haneda M, Ito H, Sasaki K, Matsukawa M, Yamada Y. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan. Adv Ther. 2020;37(3):1065-86.

Ishida Y, Murayama H, Shinfuku Y. Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan. Expert Opin Drug Saf. 2020;19(5):625-31.

Masuda T, Muto S, Fukuda K. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume. Physiol Rep. 2020;8(2):14360.

Lu H, Meyer P, Hullin R. Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how? Swiss Med Wkly. 2020;150:20341.






Review Articles